儿童期起病的免疫介导炎症性疾病与死亡风险增加相关——一项全国性研究
该研究基于丹麦全国健康登记数据,纳入1980至2018年确诊的11581例儿童期起病免疫介导炎症性疾病(pIMID)患者及99665名参照个体,随访显示pIMID患者全因死亡风险约为参照个体的3.8倍,胃肠道疾病、胃肠道癌症及淋巴增殖性疾病关联最强,作者强调多学科照护需求。
要点
- pIMID患者全因死亡校正风险比为3.8(95%CI 3.1-4.7),高于参照个体。
- 每1万人年额外死亡6.9例(95%CI 5.3-8.5)。
- 胃肠道疾病、胃肠道癌症及淋巴增殖性疾病与死亡关联最强。
核心结论
- 儿童期起病免疫介导炎症性疾病患者随访至成年早期时死亡风险约为参照个体的四倍。
- 该结果凸显pIMID的严重疾病进程,并强调多学科照护的需求。
研究设计与样本
- 基于人群的队列研究,使用丹麦全国健康登记数据。
- 纳入1980至2018年在丹麦确诊的pIMID患者,定义为18岁前登记的提示自身免疫性肝炎、原发性硬化性胆管炎、克罗恩病、溃疡性结肠炎、幼年特发性关节炎、狼疮 erythematosus 或血管炎的ICD编码。
- 共纳入11581例pIMID患者和99665名参照个体,累计随访1371994人年。
- 诊断时中位年龄12.6岁(四分位距7.9-15.9岁)。
- 采用Cox生存分析估计风险比,Aalen生存分析估计率差。
主要发现
- 随访期间pIMID患者死亡152例,参照个体死亡316例;校正风险比(aHR)为3.8(95%CI 3.1-4.7)。
- 相当于每1万人年额外死亡6.9例(95%CI 5.3-8.5)。
- 胃肠道疾病aHR 22.8(95%CI 9.6-64.1),胃肠道癌症aHR 19.2(95%CI 5.0-74.2),淋巴增殖性疾病aHR 6.8(95%CI 2.8-16.8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Paediatric-onset immune-mediated inflammatory diseases (pIMID) show more aggressive phenotypes than when diagnosed in adults. However, data on mortality are often extrapolated from adult studies. AIM: To estimate the effect of pIMID on mortality. METHODS: In a population-based cohort study using the nationwide Danish healthcare registers, we included all patients diagnosed with pIMID in Denmark from 1980 to 2018. PIMID were defined as ICD codes indicative of autoimmune hepatitis, primary sclerosing cholangitis, Crohn's disease, ulcerative colitis, juvenile idiopathic arthritis, lupus erythematosus, or vasculitis registered before age 18 years. All-cause mortality was the primary outcome; cause-specific mortality was the secondary outcome. We used Cox survival analysis to estimate hazard ratios (HR), and Aalen survival analysis to estimate rate differences. RESULTS: We included 11,581 individuals diagnosed with pIMID and 99,665 reference individuals, accounting for 1,371,994 person-years of follow-up. Median and interquartile (IQR) age at diagnosis was 12.6 (7.9-15.9) years. During follow-up, 152 patients with pIMID and 316 reference individuals died; adjusted HR (aHR) was 3.8 (95% confidence interval [CI] 3.1-4.7). This corresponded to 6.9 (95% CI: 5.3-8.5) additional deaths per 10,000 person-years. The strongest associations were found for gastrointestinal diseases (aHR 22.8; 95% CI 9.6-64.1), gastrointestinal cancers (aHR 19.2; 95% CI 5.0-74.2) and lymphoproliferative disorders (aHR 6.8; 95% CI 2.8-16.8). CONCLUSION: Patients diagnosed with pIMID have a fourfold higher risk of mortality when followed into early adulthood compared with reference individuals. This underlines the severe disease course of pIMID and highlights the need for multidisciplinary care.
引用
- Malham M, Jansson S, Ingels H, et al. Paediatric-onset immune-mediated inflammatory disease is associated with an increased mortality risk-A nationwide study. Aliment Pharmacol Ther. 2024. PMID: 38597407. doi:10.1111/apt.17994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。